Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas R. Schwab is active.

Publication


Featured researches published by Thomas R. Schwab.


Circulation Research | 1988

Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor.

Brooks S. Edwards; R. S. Zimmerman; Thomas R. Schwab; Denise M. Heublein; John C. Burnett

The current studies were designed to investigate the mechanisms in the intact anesthetized dog that control the release of atrial natriuretic factor (ANF). In vitro, mechanical stretch of atrial tissue produces an increased release of ANF. In vivo, changes in atrial pressure correlate positively with circulating ANF levels. The present investigations used 6 open-chest anesthetized dogs to evaluate the role of atrial pressure versus atrial stretch, the latter determined by atrial transmural pressure, in the release of ANF. In a paired design, animals underwent cardiac tamponade followed by constriction of the aorta and pulmonary artery. Tamponade produces a balanced increase in intra-atrial and pericardial pressures. Thus, despite an elevated atrial pressure, there is no increase in transmural pressure producing atrial stretch. Great artery constriction increases intra-atrial but not pericardial pressure, resulting in an increase in atrial transmural pressure and atrial stretch. Cardiac tamponade increased right atrial pressure (0.8 +/- 0.3 to G.6 +/- 0.6 mm Hg, p less than 0.001) and pulmonary capillary wedge pressure (3.7 +/- 0.6 to 8.8 +/- 0.6 mm Hg, P less than 0.001). Constriction of the aorta and pulmonary artery also increased right atrial pressure (1.5 +/- 0.8 to 6.3 +/- 0.8 mm Hg, p less than 0.05) and pulmonary capillary wedge pressure (4.6 +/- 0.3 to 7.8 +/- 1.0 mm Hg, p less than 0.05). Atrial transmural pressure increased only during great artery constriction.(ABSTRACT TRUNCATED AT 250 WORDS)


Mayo Clinic Proceedings | 1990

Endothelin: A New Cardiovascular Regulatory Peptide

Amir Lerman; F. L. Hildebrand; Kenneth B. Margulies; Brian O'Murchu; Mark A. Perrella; Denise M. Heublein; Thomas R. Schwab; John C. Burnett

Endothelin, a recently discovered peptide produced by endothelial cells, contracts vascular strips in vitro with greater potency than any previously known vasoconstrictor. Infusions of pharmacologic doses of endothelin in vivo result in a prolonged pressor response and a preferential impairment of renal hemodynamic and excretory functions. Endothelin also directly stimulates the release of aldosterone from the adrenal gland and inhibits renin release in vitro. A highly sensitive and specific radioimmunoassay has confirmed that endothelin circulates in human plasma, and increased plasma endothelin levels have been associated with various cardiovascular disease states. This review summarizes the current knowledge about the molecular biologic features and physiologic actions of endothelin and also explores the role of endothelin, through its local and systemic function, as a regulator of vascular tone in normal and pathophysiologic states.


Circulation Research | 1987

Cardio-renal-endocrine dynamics during stepwise infusion of physiologic and pharmacologic concentrations of atrial natriuretic factor in the dog.

R. S. Zimmerman; J. A. Schirger; Brooks S. Edwards; Thomas R. Schwab; Denise M. Heublein; John C. Burnett

Infusion of alpha-human atrial natriuretic factor (alpha-h-ANF) into pentobarbital anesthetized dogs (n = 10) at 0.0025, 0.005, 0.01, and 0.3 micrograms/kg/min was performed to differentiate the physiologic actions of atrial natriuretic factor from its pharmacologic actions. The lowest doses of atrial natriuretic factor infusion resulted in circulating levels that were previously produced by 0-10% saline volume expansion. At the lowest infusion rate, circulating ANF increased 31 +/- 3 pg/ml, resulting in a significant increase in absolute sodium excretion, fractional excretion of sodium, and fractional excretion of lithium, and a significant decrease in urine osmolality. A greater change in circulating atrial natriuretic factor (96 +/- 12 pg/ml) was required to significantly decrease right atrial pressure, cardiac output, and plasma renin activity, and to increase systemic vascular resistance and total and fractional excretion of potassium. The highest dose of atrial natriuretic factor infused was required to decrease arterial pressure and renal vascular resistance. The present study demonstrates that atrial natriuretic factor is natriuretic and diuretic at physiologic concentrations; at low concentrations, atrial natriuretic factor appears to decrease the whole kidney proximal tubular reabsorption of sodium and does not affect glomerular filtration rate; a greater (but physiologic) change in circulating atrial natriuretic factor is required to significantly decrease cardiac output, cardiac filling pressure, and plasma renin activity than is required to significantly increase sodium excretion; and a decrease in systemic arterial pressure and vascular resistance does not occur at physiologic concentrations of atrial natriuretic factor.


Mayo Clinic Proceedings | 1986

The Relationship Between Atrial Granularity and Circulating Atrial Natriuretic Peptide in Hamsters With Congestive Heart Failure

Brooks S. Edwards; Douglas M. Ackermann; Thomas R. Schwab; Denise M. Heublein; William D. Edwards; Lester E. Wold; John C. Burnett

The BIO 14.6 strain of hamster is a model of familial cardiomyopathy complicated by congestive heart failure, sodium retention, and edema. In previous studies, bioassay techniques have demonstrated that the cardiac content of atrial natriuretic peptide (ANP) is reduced in these animals. On the basis of this observation, the syndrome of congestive heart failure has been hypothesized to be due to a deficiency in ANP. The current study was designed to correlate the cardiac content of ANP (determined by immunohistochemical techniques) with plasma circulating ANP (determined by radioimmunoassay). alpha-ANP antibodies were used for both determinations. The content of ANP in the atria was based on the degree of immunoreactive staining present (1 = lowest; 5 = highest), as graded by two observers. The mean granularity score of the cardiomyopathic hamsters was decreased (2.1 +/- 0.3) in comparison with that of age- and sex-matched control animals (3.5 +/- 0.5; P less than 0.05). In contrast, circulating immunoreactive ANP was higher in the hamsters with congestive heart failure than in the control animals--185.5 +/- 27.2 pg/ml versus 77.7 +/- 10.8 pg/ml (P less than 0.005). This study demonstrates that an inverse relationship exists between ANP content in the atria and circulating ANP. Furthermore, this study suggests that these hamsters with congestive heart failure are not deficient in ANP; rather, secretion of ANP is stimulated and storage of the peptide, represented by atrial granularity, is reduced.


Mayo Clinic Proceedings | 1998

Unrecognized Severe Postoperative Hypercapnia: A Case of Apneic Oxygenation

Najib Ayas; Larry R. Bergstrom; Thomas R. Schwab; Bradly J. Narr

Transcutaneous pulse oximetry is increasingly being used to supplant arterial blood gas measurement as a means to monitor oxygenation. Previous studies have demonstrated that, despite inadequate ventilation, oxygenation can be maintained during delivery of supplemental oxygen by a process known as diffusion respiration. In this setting, severe hypercapnia and acidosis rapidly develop. This case report demonstrates that pulse oximetry is an unreliable means to monitor adequacy of ventilation. A 75-year-old woman in good health suffered a fracture of the right hip that necessitated arthroplasty. During postoperative recovery, she remained unresponsive while receiving 100% oxygen through an endotracheal tube; mechanical ventilation was not used. Pulse oximetry indicated a blood oxygen saturation of 94 to 96%; however, results of blood gas studies 3 1/2 hours postoperatively revealed profound hypercapnia (arterial carbon dioxide tension, 265 mm Hg) and acidosis (pH, 6.65) but confirmed normal oxygen levels (arterial oxygen tension, 213 mm Hg). Assisted ventilation resulted in normalization of the blood gases and an improved level of consciousness. The patient was then transferred to Mayo Clinic Rochester and had an uneventful recovery.


The New England Journal of Medicine | 1986

Atrial Endocrine Function in Humans with Artificial Hearts

Thomas R. Schwab; Brooks S. Edwards; William C. DeVries; R. S. Zimmerman; John C. Burnett

THE artificial heart is currently under investigation as a means to restore cardiac function in patients with end-stage heart failure. During implantation, the Jarvik-7 artificial heart is anastomosed to the native pulmonary artery, aorta, and cardiac atria.1 Postoperatively, approximately 95 percent of the native atrial tissue remains in situ. The atria play a key part in the control of body-fluid homeostasis by monitoring blood volume and initiating appropriate changes in urine flow and sodium excretion. Until recently the polyuria that may accompany atrial tachycardia and atrial distension has been attributed to reflex stimulation of subendocardial neuronal stretch receptors.2 , 3 In 1981 .xa0.xa0.


Experimental Biology and Medicine | 1987

Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction

John C. Burnett; Gabor M. Rubanyi; Brooks S. Edwards; Thomas R. Schwab; R. S. Zimmerman; Paul M. Vanhoutte

Abstract Studies were performed in isolated, Langendorff-perfused rat hearts and anesthetized dogs to determine the effects of synthetic atrial natriuretic peptide (ANP 8-33) on the coronary circulation. In vitro studies in the rat examined coronary flow dynamics to ANP 8-33 over a defined range from physiologic to pharmacologic concentrations. No changes in coronary flow or chronotropic and inotropic function of the isolated Langendorff-perfused heart were observed in response to increasing concentrations of ANP 8-33 (102 to 106 pg/ml). In the dog, a low, nonhypotensive dose of ANP 8-33 (0.05 μg/kg/min) decreased cardiac output with no change in coronary blood flow or coronary vascular resistance. At a high, hypotensive dose (0.3 μg/kg/min) ANP 8-33 decreased cardiac output in association with transient coronary vasodilation. Continued infusion resulted in a decrease in coronary blood flow and arterial pressure with no change in coronary vascular resistance. Thus, in vitro physiologic and pharmacologic concentrations of ANP, or in vivo low concentrations of ANP, do not result in an alteration in coronary flow. In vivo ANP 8-33, at both nonhypotensive and hypotensive concentrations, decreased cardiac output in the absence of coronary vasoconstriction.


American Journal of Physiology-heart and Circulatory Physiology | 1992

Cardiac atrial natriuretic factor during evolution of congestive heart failure

Mark A. Perrella; Thomas R. Schwab; B. O'murchu; M. M. Redfield; Chi-Ming Wei; B. S. Edwards; John C. Burnett


The Journal of Clinical Endocrinology and Metabolism | 1987

Atrial Natriuretic Peptide during Mineralocorticoid Escape in the Human

R. S. Zimmerman; Brooks S. Edwards; Thomas R. Schwab; Denise M. Heublein; John C. Burnett


Journal of the American College of Cardiology | 1991

Atrial, ventricular, and plasma atrial natriuretic factor during the evolution of congestive heart failure

Mark A. Perrella; Thomas R. Schwab; Brian O'Murchu; Brooks S. Edwards; John C. Burnett

Collaboration


Dive into the Thomas R. Schwab's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark A. Perrella

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge